Bates Blaine A, Bates Kylee E, Boris Spencer A, Wessman Colin, Stone David, Bryan Justin, Davis Mary F, Bailey Matthew H
Department of Biology, Brigham Young University, Provo, UT 84061, USA; Department of Chemical Engineering, Brigham Young University, Provo, UT 84602, USA.
Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA.
HGG Adv. 2025 Apr 10;6(2):100405. doi: 10.1016/j.xhgg.2025.100405. Epub 2025 Jan 11.
Using rare cancer predisposition alleles derived from The Cancer Genome Atlas (TCGA) and high cancer prevalence (14% of participants) in All of Us (version 6), we assessed the impact of these rare alleles on cancer occurrence in six broad groups of genetic similarity provided by All of Us: African/African American (AFR), Admixed American/Latino (AMR), East Asian (EAS), European (EUR), Middle Eastern (MID), or South Asian (SAS). We observed that germline susceptibility to cancer consistently replicates in EUR-like participants but less so in other participants. We found that All of Us participants from the EUR (p = 1.8 × 10), AFR (p = 0.018), and MID (p = 0.0083) genetic similarity groups who carry a rare pathogenic mutation are more likely to have cancer than those without a rare pathogenic mutation. With the advent of combining medical records and genetic mutations, we also performed a phenome-wide association study (PheWAS) to assess the effect of pathogenic variants on additional phenotypes. This analysis again showed several associations between predisposition variants and cancer in EUR-like participants, but fewer in those of the other genetic similarity groups. As All of Us grows to 1 million participants, our projections suggest sufficient power (>99%) to detect cancer-associated variants that are common, but limited power (∼28%) to detect rare mutations when using the entire cohort. This study provides preliminary insights into genetic predispositions to cancer across a diverse cohort and demonstrates the value of All of Us as a resource for cancer research.
利用源自癌症基因组图谱(TCGA)的罕见癌症易感性等位基因以及“我们所有人”(第6版)中较高的癌症患病率(14%的参与者),我们评估了这些罕见等位基因对“我们所有人”提供的六组广泛遗传相似性人群中癌症发生的影响:非洲/非裔美国人(AFR)、混血美国人/拉丁裔(AMR)、东亚人(EAS)、欧洲人(EUR)、中东人(MID)或南亚人(SAS)。我们观察到,癌症的种系易感性在类似欧洲人的参与者中始终具有重复性,但在其他参与者中则不然。我们发现携带有罕见致病突变的“我们所有人”中来自EUR(p = 1.8 × 10)、AFR(p = 0.018)和MID(p = 0.0083)遗传相似性组的参与者比没有罕见致病突变的参与者更有可能患癌症。随着医疗记录与基因突变相结合的出现,我们还进行了全表型关联研究(PheWAS),以评估致病变异对其他表型的影响。该分析再次显示,在类似欧洲人的参与者中,易感性变异与癌症之间存在若干关联,但在其他遗传相似性组的参与者中则较少。随着“我们所有人”的参与者人数增长到100万,我们的预测表明,在使用整个队列时,有足够的能力(>99%)检测常见的癌症相关变异,但检测罕见突变的能力有限(约28%)。这项研究为不同队列中癌症的遗传易感性提供了初步见解,并证明了“我们所有人”作为癌症研究资源的价值。